Seoulin Bioscience Co.,Ltd.
Financials
Valuation Metrics
Seoulin Bioscience Co.,Ltd.'s Market Cap is ₩391B. At end of 2025 it was ₩605B. Ranked #1897 of 2,436 in KR market (top 78%), #1180 of 1,649 on KOSDAQ (top 72%), #205 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 39.11B KRW | KR#1,897/2,436 Sec#205/234 |
| Revenue | 78.58B KRW | KR#1,545/2,436 Sec#98/234 |
| Net Income | 434.6M KRW | KR#1,470/2,436 Sec#101/234 |
| Total Assets | 119.42B KRW | KR#1,618/2,436 Sec#131/234 |
| Net Assets | 85.34B KRW | KR#1,504/2,436 Sec#124/234 |
| Employees | 110 | KR#1,562/2,436 Sec#121/234 |
| Value | ||
| P/E | 89.98x | KR#1,434/2,436 Sec#94/234 |
| P/B | 0.46x | KR#710/2,436 Sec#23/234 |
| P/S | 0.50x | KR#925/2,436 Sec#39/234 |
| EV/EBITDA | 52.03x | KR#1,348/2,436 Sec#91/234 |
| Profitability | ||
| ROE | 0.51% | KR#1,460/2,436 Sec#101/234 |
| ROA | 0.36% | KR#1,434/2,436 Sec#100/234 |
| Op. Margin | 0.98% | KR#1,481/2,436 Sec#109/234 |
| Revenue Growth | 8.28% | KR#1,002/2,436 Sec#92/234 |
| Earnings Growth | -47.89% | KR#1,187/2,436 Sec#76/234 |
| Financial Health | ||
| Debt Ratio | 139.93% | KR#1,033/2,436 Sec#120/234 |
| Total Debt | 11.76B KRW | KR#1,565/2,436 Sec#144/234 |
| Cash | 10.85B KRW | KR#1,632/2,436 Sec#126/234 |
| Current Ratio | 2.23x | KR#845/2,436 Sec#98/234 |
| Net Debt/EBITDA | 1.18x | KR#817/2,436 Sec#57/234 |
| Dividend | ||
| Div. Yield | 2.38% | KR#797/2,436 Sec#42/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -40.27% | KR#1,842/2,436 Sec#162/234 |
| 1M Return | -6.87% | KR#1,558/2,436 Sec#157/234 |
| From 52W High | -46.05% | KR#1,019/2,436 Sec#80/234 |
| 1Y MDD | -48.16% | KR#846/2,436 Sec#70/234 |
| Trading | ||
| Volume | 16,318 shares | KR#1,943/2,436 Sec#193/234 |
| Foreign Own. | 3.10% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 56 KRW | KR#1,439/2,436 Sec#101/234 |
| BPS | 9,470 KRW | KR#975/2,436 Sec#68/234 |
Company Info
SEORIN BIO, founded in 1984, converted to a corporation in 1994, and listed on KOSDAQ in 2005, is a specialized bio company. It provides raw and subsidiary materials for biopharmaceuticals and reagents/equipment for basic life science research, offering total solutions across the bio industry with over 58,000 items. The company supplies core raw materials like cell culture media through global partnerships and supports customer R&D with its industry experience and cold chain logistics infrastructure. SEORIN BIO is headquartered in Seongnam-si, Gyeonggi-do.